Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

This Study is a Non-Randomized, Open-Label, Multi-Center Phase II Study of GW786034 to Evaluate the Administration of Oral GW786034 in Subjects With Ovarian Cancer.

Next Previous
Trial Profile

This Study is a Non-Randomized, Open-Label, Multi-Center Phase II Study of GW786034 to Evaluate the Administration of Oral GW786034 in Subjects With Ovarian Cancer.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Sponsors GSK

Most Recent Events

  • 03 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 18 Sep 2008 Positive results reported at ESMO according to GlaxoSmithKline media release.
  • 12 Sep 2008 Interim results will be reported at the 33rd Congress of the European Society for Medical Oncology (ESMO), according to a GlaxoSmithKline media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top